Baxter 3Q Revenues: $4.2 billion (+13%) 3Q Earnings: $468 million (-14%) YTD Revenues: $12.2 billion (+15%) YTD Earnings: $1.5 billion (-8%) Comments: BioScience revenues were $1.7 billion, up 8%, driven primarily by double-digit growth and continued strong demand for hemophilia therapies (+11% to $942 million), including ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] and FEIBA (an inhibitor therapy). BioScience sales, including vaccines, were up 7%. Medical Produc...